Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms.

Chien YL, Liu CM, Shan JC, Lee HJ, Hsieh MH, Hwu HG, Chiou LC.

Psychoneuroendocrinology. 2015 Mar;53:1-9. doi: 10.1016/j.psyneuen.2014.12.012. Epub 2014 Dec 20.

PMID:
25560205
2.

High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.

Kawai N, Yamakawa Y, Baba A, Nemoto K, Tachikawa H, Hori T, Asada T, Iidaka T.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):1009-14. Epub 2006 Apr 27.

PMID:
16644082
3.

Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia.

Rocca P, Montemagni C, Castagna F, Giugiario M, Scalese M, Bogetto F.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):373-9. doi: 10.1016/j.pnpbp.2009.01.002. Epub 2009 Jan 11.

PMID:
19211031
4.

[Differentiation of deficit and non-deficit schizophrenia based on cognitive functions].

Polgár P.

Ideggyogy Sz. 2011 Mar 30;64(3-4):128-32. Hungarian.

PMID:
21545010
5.

Intact Wisconsin Card Sorting Test performance: implications for the role of executive function in schizophrenia.

Thurston-Snoha BJ, Lewine RR.

Br J Clin Psychol. 2007 Sep;46(Pt 3):361-9.

PMID:
17535528
6.

Neurocognitive profile and its association with psychopathology in first-degree relatives of patients with schizophrenia. a case-control study.

Scala S, Lasalvia A, Cristofalo D, Bonetto C, Ruggeri M.

Psychiatry Res. 2012 Dec 30;200(2-3):137-43. doi: 10.1016/j.psychres.2012.05.006. Epub 2012 May 29.

PMID:
22652345
7.

[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].

Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.

Encephale. 2008 Dec;34(6):557-62. doi: 10.1016/j.encep.2007.12.005. Epub 2008 Jul 9. French.

PMID:
19081451
8.

Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study.

Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, Casacchia M.

Acta Psychiatr Scand. 1997 Jan;95(1):40-3.

PMID:
9051159
9.

[Psychopathologic and cognitive investigations in schizophrenia].

Farkas M.

Orv Hetil. 2009 Mar 1;150(9):423-9. doi: 10.1556/OH.2009.28530. Hungarian.

PMID:
19228571
10.

The effect of verbalization strategy on Wisconsin Card Sorting Test performance in schizophrenic patients receiving classical or atypical antipsychotics.

Rossi A, Daneluzzo E, Tomassini A, Struglia F, Cavallaro R, Smeraldi E, Stratta P.

BMC Psychiatry. 2006 Jan 26;6:3.

11.

Negative symptoms and executive function in schizophrenia: does their relationship change with illness duration?

Bagney A, Rodriguez-Jimenez R, Martinez-Gras I, Sanchez-Morla EM, Santos JL, Jimenez-Arriero MA, Lobo A, McGorry PD, Palomo T.

Psychopathology. 2013;46(4):241-8. doi: 10.1159/000342345. Epub 2012 Nov 9.

PMID:
23147471
12.

Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.

Lee SM, Chou YH, Li MH, Wan FJ, Yen MH.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1101-7. Epub 2007 Apr 1.

PMID:
17475386
14.

Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function.

Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL.

Arch Gen Psychiatry. 2006 Dec;63(12):1325-35. Erratum in: Arch Gen Psychiatry. 2007 Mar;64(3):360.

PMID:
17146007
15.

HTTLPR functional polymorphism in schizophrenia: executive functions vs. sustained attention dissociation.

Bosia M, Anselmetti S, Pirovano A, Ermoli E, Marino E, Bramanti P, Smeraldi E, Cavallaro R.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):81-5. doi: 10.1016/j.pnpbp.2009.10.001. Epub 2009 Oct 8.

PMID:
19818823
16.

[Could we use a serum level of glycine as a prognostic factor of its efficacy in schizophrenic patients?].

Strzelecki D, Rabe-Jabłońska J.

Psychiatr Pol. 2010 May-Jun;44(3):395-404. Polish.

PMID:
20672518
17.

Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects.

Altshuler LL, Ventura J, van Gorp WG, Green MF, Theberge DC, Mintz J.

Biol Psychiatry. 2004 Oct 15;56(8):560-9.

PMID:
15476685
18.

Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia.

Goto N, Yoshimura R, Kakeda S, Moriya J, Hayashi K, Ikenouchi-Sugita A, Umene-Nakano W, Hori H, Ueda N, Korogi Y, Nakamura J.

Hum Psychopharmacol. 2009 Dec;24(8):639-45. doi: 10.1002/hup.1070.

PMID:
19946939
19.

Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.

Kim SW, Shin IS, Kim JM, Lee SH, Lee YH, Yang SJ, Yoon JS.

Hum Psychopharmacol. 2009 Oct;24(7):565-73. doi: 10.1002/hup.1057.

PMID:
19790174
20.

Neurocognition, psychopathology, and subjective disturbances in schizophrenia: a comparison between short-term and remitted patients.

Comparelli A, De Carolis A, Corigliano V, Romano S, Kotzalidis G, Brugnoli R, Tamorri S, Curto M, Tatarelli R, Ferracuti S, Girardi P.

Compr Psychiatry. 2012 Oct;53(7):931-9. doi: 10.1016/j.comppsych.2012.02.007. Epub 2012 Mar 22.

PMID:
22444951

Supplemental Content

Support Center